1Eisenberg DA. Cholesterol lowering in the management of coronary artery disease: the clinical implication of recent trials.Am J Med, 1998,28: 53-64.
2Gottl AM Jr. Results of recent large cholesterol-lowering trials and implications for clinical management. Am J Cardiol, 1997,79: 1663-1666.
3Rosenson RS, Tangney CC . Antithrombotic properties of statins: implication for cardiovascular event reduction. JAMA,1998,279: 1643-1650.
4Humphries SE, Tata F, Henry I, et al. The isolation ,characterization, and chromosomal assignment of the gene for human 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCoA reductase). Hum Genet, 1985, 71: 254-258.
5Leltersdorf E, Hwang M, Luskey KL. ScrF1 polymorphism in the 2nd intron of the HMGCR gene. Nucleic Acids Res, 1990,18: 5584.
6Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma,without use of the preparative ultracentrifuge. Clin Chem, 1972,18: 499-502.
7Goldstein JL, Brown MS. Regulation of the mevalonate pathway.Nature, 1990,343: 425-430.
8Musanti R, Giorginl L, Lovisolo P, et al. Inhibition of acyl-CoA:cholesterol acyhransferase decreases apolipoprotein B-100-containing lipoprotein secretion from HepG2 cells. J Lipid Res,1996,37 : 1-14.
9Miyazakl A, Koga T. Pravastatin sodium, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, decreases serum total cholesterol in Japanese White rabbits by two different mechanisms. Atherosclerosis, 2002, 162 : 299-306.
10Karpe F, Hellenius ML, Hamsten A. Differences in postprandial concentrations of very-low-density lipoprotein and chylomicron remnants between normotriglyceridemic and hypertriglyceridemic men with and without coronary heart disease. Metabolism, 1999,48: 301-307.
